281 related articles for article (PubMed ID: 30401652)
1. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
Vaidya B; Parvathaneni V; Kulkarni NS; Shukla SK; Damon JK; Sarode A; Kanabar D; Garcia JV; Mitragotri S; Muth A; Gupta V
Int J Biol Macromol; 2019 Feb; 122():338-347. PubMed ID: 30401652
[TBL] [Abstract][Full Text] [Related]
2. Nanotechnology Based Repositioning of an Anti-Viral Drug for Non-Small Cell Lung Cancer (NSCLC).
Parvathaneni V; Goyal M; Kulkarni NS; Shukla SK; Gupta V
Pharm Res; 2020 Jun; 37(7):123. PubMed ID: 32514688
[TBL] [Abstract][Full Text] [Related]
3. Development and in vitro evaluation of core-shell type lipid-polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer.
Mandal B; Mittal NK; Balabathula P; Thoma LA; Wood GC
Eur J Pharm Sci; 2016 Jan; 81():162-71. PubMed ID: 26517962
[TBL] [Abstract][Full Text] [Related]
4. Biomimetic nanoparticle loading obatoclax mesylate for the treatment of non-small-cell lung cancer (NSCLC) through suppressing Bcl-2 signaling.
Chen S; Ren Y; Duan P
Biomed Pharmacother; 2020 Sep; 129():110371. PubMed ID: 32563984
[TBL] [Abstract][Full Text] [Related]
5. Effect of a 2-HP-β-Cyclodextrin Formulation on the Biological Transport and Delivery of Chemotherapeutic PLGA Nanoparticles.
Zheng K; Huang Z; Huang J; Liu X; Ban J; Huang X; Luo H; Chen Z; Xie Q; Chen Y; Lu Z
Drug Des Devel Ther; 2021; 15():2605-2618. PubMed ID: 34168432
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib loaded chitosan nanoparticles: Formulation, physicochemical characterization and cytotoxic potential.
Pandey P; Dua K; Dureja H
Int J Biol Macromol; 2019 Oct; 139():1304-1316. PubMed ID: 31404602
[TBL] [Abstract][Full Text] [Related]
7. Central composite designed formulation, characterization and in vitro cytotoxic effect of erlotinib loaded chitosan nanoparticulate system.
Pandey P; Chellappan DK; Tambuwala MM; Bakshi HA; Dua K; Dureja H
Int J Biol Macromol; 2019 Dec; 141():596-610. PubMed ID: 31494160
[TBL] [Abstract][Full Text] [Related]
8. Nano-synergistic combination of Erlotinib and Quinacrine for non-small cell lung cancer (NSCLC) therapeutics - Evaluation in biologically relevant in-vitro models.
Kulkarni NS; Vaidya B; Gupta V
Mater Sci Eng C Mater Biol Appl; 2021 Feb; 121():111891. PubMed ID: 33579503
[TBL] [Abstract][Full Text] [Related]
9. Erlotinib entrapped in cholesterol-depleting cyclodextrin nanoparticles shows improved antitumoral efficacy in 3D spheroid tumors of the lung and the liver.
Varan G; Akkın S; Demirtürk N; Benito JM; Bilensoy E
J Drug Target; 2021 Apr; 29(4):439-453. PubMed ID: 33210947
[TBL] [Abstract][Full Text] [Related]
10. Enhanced Chemotherapeutic Efficacy of PLGA-Encapsulated Epigallocatechin Gallate (EGCG) Against Human Lung Cancer.
Zhang L; Chen W; Tu G; Chen X; Lu Y; Wu L; Zheng D
Int J Nanomedicine; 2020; 15():4417-4429. PubMed ID: 32606686
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib Loaded Inhalable Polymeric Nanocarriers against Non-Small Cell Lung Cancer.
Shukla SK; Kulkarni NS; Farrales P; Kanabar DD; Parvathaneni V; Kunda NK; Muth A; Gupta V
Pharm Res; 2020 Mar; 37(3):67. PubMed ID: 32166411
[TBL] [Abstract][Full Text] [Related]
12. Development of pharmaceutically scalable inhaled anti-cancer nanotherapy - Repurposing amodiaquine for non-small cell lung cancer (NSCLC).
Parvathaneni V; Kulkarni NS; Chauhan G; Shukla SK; Elbatanony R; Patel B; Kunda NK; Muth A; Gupta V
Mater Sci Eng C Mater Biol Appl; 2020 Oct; 115():111139. PubMed ID: 32600728
[TBL] [Abstract][Full Text] [Related]
13. Characterisation of 2-HP-β-cyclodextrin-PLGA nanoparticle complexes for potential use as ocular drug delivery vehicles.
Li F; Wen Y; Zhang Y; Zheng K; Ban J; Xie Q; Wen Y; Liu Q; Chen F; Mo Z; Liu L; Chen Y; Lu Z
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4097-4108. PubMed ID: 31663388
[No Abstract] [Full Text] [Related]
14. Nano-Particulated Erlotinib Compound System in Alleviation of Lung Cancer.
Zhu Y; Shen L; Zhou Y
J Biomed Nanotechnol; 2021 Oct; 17(10):1984-1992. PubMed ID: 34706798
[TBL] [Abstract][Full Text] [Related]
15. Inhalable resveratrol-cyclodextrin complex loaded biodegradable nanoparticles for enhanced efficacy against non-small cell lung cancer.
Wang X; Parvathaneni V; Shukla SK; Kulkarni NS; Muth A; Kunda NK; Gupta V
Int J Biol Macromol; 2020 Dec; 164():638-650. PubMed ID: 32693132
[TBL] [Abstract][Full Text] [Related]
16. Anti-proliferate and apoptosis triggering potential of methotrexate-transferrin conjugate encapsulated PLGA nanoparticles with enhanced cellular uptake by high-affinity folate receptors.
Parmar A; Jain A; Uppal S; Mehta SK; Kaur K; Singh B; Sandhir R; Sharma S
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):704-719. PubMed ID: 29745729
[TBL] [Abstract][Full Text] [Related]
17. Apigenin-Loaded PLGA-DMSA Nanoparticles: A Novel Strategy to Treat Melanoma Lung Metastasis.
Sen R; Ganguly S; Ganguly S; Debnath MC; Chakraborty S; Mukherjee B; Chattopadhyay D
Mol Pharm; 2021 May; 18(5):1920-1938. PubMed ID: 33780261
[TBL] [Abstract][Full Text] [Related]
18. Development of Gemcitabine Loaded PLGA/Lecithin Nanoparticles for Non-Small Cell Lung Cancer Therapy.
Esim O; Ozkan CK; Sarper M; Savaser A; Ozkan Y
Curr Drug Deliv; 2020; 17(7):622-628. PubMed ID: 32394837
[TBL] [Abstract][Full Text] [Related]
19. A novel nanoformulation of PLGA with high non-ionic surfactant content improves in vitro and in vivo PTX activity against lung cancer.
Jiménez-López J; El-Hammadi MM; Ortiz R; Cayero-Otero MD; Cabeza L; Perazzoli G; Martin-Banderas L; Baeyens JM; Prados J; Melguizo C
Pharmacol Res; 2019 Mar; 141():451-465. PubMed ID: 30634051
[TBL] [Abstract][Full Text] [Related]
20. PEGylated polypeptide lipid nanocapsules to enhance the anticancer efficacy of erlotinib in non-small cell lung cancer.
Kim J; Ramasamy T; Choi JY; Kim ST; Youn YS; Choi HG; Yong CS; Kim JO
Colloids Surf B Biointerfaces; 2017 Feb; 150():393-401. PubMed ID: 27825759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
